Form 1-K Issuer Information


FORM 1-K

UNITED STATE
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 1-K

OMB APPROVAL

OMB Number:  ####-####

Estimated average burden hours per response: ##.#

1-K: Filer Information

Issuer CIK
0000058411 
Issuer CCC
XXXXXXXX 
Is filer a shell company?
o Yes x No
Is the electronic copy of an official filing submitted in paper format?
o
File Number
 
Is this filing by a successor company pursuant to Rule 257(b)(5) resulting from a merger or other business combination?
o Yes x No
Successor File Number
 
Is this a LIVE or TEST Filing?
x LIVE o TEST
Would you like a Return Copy?
o
Period
12-31-2022 

Submission Contact Information

Name
 
Phone
 
E-Mail Address
 
Notify via Filing Website only?
o

1-K: Tab 1 Notification

This Form 1-K is to provide an
o Annual Report x Special Financial Report for the fiscal year
Fiscal Year End
12-31-2022 
Exact name of issuer as specified in the issuer's charter
Lee Pharmaceuticals, Inc. 
CIK
0000058411 
Jurisdiction of Incorporation / Organization
COLORADO  
I.R.S. Employer Identification Number
95-2680312 

Address of Principal Executive Offices

Address 1
11 N WATER STREET 
Address 2
 
City
MOBILE 
State/Country
NEVADA  
Mailing Zip/ Postal Code
36602 
Phone
678-999-6242 
Title of each class of securities issued pursuant to Regulation A
Common Stock 

1-K: Summary Information Regarding Prior Offering and Proceeds

Summary Information

oThe following information must be provided for any Regulation A offering that has terminated or completed prior to the filing of this Form 1-K, unless such information has been previously reported in a manner permissible under Rule 257. If such information has been previously reported, check this box and leave the rest of Part I blank.

Commission File Number of the offering statement
024-11991 
Date of qualification of the offering statement
01-17-2023 
Date of commencement of the offering
01-19-2023 
Amount of securities qualified to be sold in the offering
5000000000 
Amount of securities sold in the offering
25000000 
Price per security
$ 0.0100 
The portion of aggregate sales attributable to securities sold on behalf of the issuer
$ 250000.00 
The portion of the aggregate sales attributable to securities sold on behalf of selling securityholders
$ 0.00 

Fees in connection with this offering and names of service providers.

Underwriters - Name of Service Provider
Underwriters - Fees
$  
Sales Commissions - Name of Service Provider
Sales Commissions - Fee
$  
Finders' Fees - Name of Service Provider
Finders' Fees - Fees
$  
Audit - Name of Service Provider
Audit - Fees
$  
Legal - Name of Service Provider
JDT Legal
PLLC
Legal - Fees
$ 15000.00 
Promoters - Name of Service Provider
Promoters - Fees
$  
Blue Sky Compliance - Name of Service Provider
Blue Sky Compliance - Fees
$  
CRD Number of any broker or dealer listed
 
Net proceeds to the issuer
$ 235000.00 
Clarification of responses (if necessary)
 
Lee Pharmaceuticals (PK) (USOTC:LPHM)
๊ณผ๊ฑฐ ๋ฐ์ดํ„ฐ ์ฃผ์‹ ์ฐจํŠธ
๋ถ€ํ„ฐ 5์›”(5) 2024 ์œผ๋กœ 6์›”(6) 2024 Lee Pharmaceuticals (PK) ์ฐจํŠธ๋ฅผ ๋” ๋ณด๋ ค๋ฉด ์—ฌ๊ธฐ๋ฅผ ํด๋ฆญ.
Lee Pharmaceuticals (PK) (USOTC:LPHM)
๊ณผ๊ฑฐ ๋ฐ์ดํ„ฐ ์ฃผ์‹ ์ฐจํŠธ
๋ถ€ํ„ฐ 6์›”(6) 2023 ์œผ๋กœ 6์›”(6) 2024 Lee Pharmaceuticals (PK) ์ฐจํŠธ๋ฅผ ๋” ๋ณด๋ ค๋ฉด ์—ฌ๊ธฐ๋ฅผ ํด๋ฆญ.